2. Academic Validation
  3. A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2

A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2

  • Nat Commun. 2020 Aug 25;11(1):4252. doi: 10.1038/s41467-020-17986-9.
Hanjun Zhao # 1 2 3,  Kelvin K W To # 1 2 3 4 5,  Kong-Hung Sze # 1 2,  Timothy Tin-Mong Yung 2 3,  Mingjie Bian 6,  Hoiyan Lam 2 3,  Man Lung Yeung 1 2 3 5,  Cun Li 2 3,  Hin Chu 1 2 3,  Kwok-Yung Yuen 7 8 9 10 11
Affiliations

Affiliations

  • 1 Li Ka Shing Faculty of Medicine, State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
  • 2 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
  • 3 Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Hong Kong, China.
  • 4 Li Ka Shing Faculty of Medicine, Carol Yu Centre for Infection, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
  • 5 The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
  • 6 School of Life Science, Anhui Normal University, Wuhu, Anhui, China.
  • 7 Li Ka Shing Faculty of Medicine, State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. kyyuen@hku.hk.
  • 8 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. kyyuen@hku.hk.
  • 9 Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Hong Kong, China. kyyuen@hku.hk.
  • 10 Li Ka Shing Faculty of Medicine, Carol Yu Centre for Infection, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. kyyuen@hku.hk.
  • 11 The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China. kyyuen@hku.hk.
  • # Contributed equally.
PMID: 32843628 DOI: 10.1038/s41467-020-17986-9
Abstract

The 2019 novel respiratory virus (SARS-CoV-2) causes COVID-19 with rapid global socioeconomic disruptions and disease burden to healthcare. The COVID-19 and previous emerging virus outbreaks highlight the urgent need for broad-spectrum antivirals. Here, we show that a defensin-like peptide P9R exhibited potent Antiviral activity against pH-dependent viruses that require endosomal acidification for virus Infection, including the enveloped pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, coronaviruses (SARS-CoV-2, MERS-CoV and SARS-CoV), and the non-enveloped rhinovirus. P9R can significantly protect mice from lethal challenge by A(H1N1)pdm09 virus and shows low possibility to cause drug-resistant virus. Mechanistic studies indicate that the Antiviral activity of P9R depends on the direct binding to viruses and the inhibition of virus-host endosomal acidification, which provides a proof of concept that virus-binding alkaline peptides can broadly inhibit pH-dependent viruses. These results suggest that the dual-functional virus- and host-targeting P9R can be a promising candidate for combating pH-dependent respiratory viruses.

Figures
Products